Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strome, S. E.
Right arrow Articles by Chen, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strome, S. E.
Right arrow Articles by Chen, L.
[Cancer Research 63, 6501-6505, October 1, 2003]
© 2003 American Association for Cancer Research

Immunology

B7-H1 Blockade Augments Adoptive T-Cell Immunotherapy for Squamous Cell Carcinoma1

Scott E. Strome2,,3, Haidong Dong2, Hideto Tamura, Stephen G. Voss, Dallas B. Flies, Koji Tamada, Diva Salomao, John Cheville, Fumiya Hirano, Wei Lin, Jan L. Kasperbauer, Karla V. Ballman and Lieping Chen

Departments of Otolaryngology [S. E. S., S. G. V., W. L., J. L. K.], Immunology [H. D., H. T., D. B. F., K. T., F. H., L. C.], Laboratory Medicine and Pathology [D. S., J. C.], and Biostatistics [K. V. B.], Mayo Clinic, Rochester, Minnesota 55905

In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T cells cured 60% of animals. These data support B7-H1 blockade as a new approach to enhance the efficacy of T-cell immunotherapy.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
K. Wu, I. Kryczek, L. Chen, W. Zou, and T. H. Welling
Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
Cancer Res., October 15, 2009; 69(20): 8067 - 8075.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Zhang, T. F. Gajewski, and J. Kline
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Blood, August 20, 2009; 114(8): 1545 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. S. Kim, G. B. Park, H.-K. Lee, H. Song, I.-H. Choi, W. J. Lee, and D. Y. Hur
Cross-Linking of B7-H1 on EBV-Transformed B Cells Induces Apoptosis through Reactive Oxygen Species Production, JNK Signaling Activation, and fasL Expression
J. Immunol., November 1, 2008; 181(9): 6158 - 6169.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Iuchi, S. Teitz-Tennenbaum, J. Huang, B. G. Redman, S. D. Hughes, M. Li, G. Jiang, A. E. Chang, and Q. Li
Interleukin-21 Augments the Efficacy of T-Cell Therapy by Eliciting Concurrent Cellular and Humoral Responses
Cancer Res., June 1, 2008; 68(11): 4431 - 4441.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Berger, R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. Koren-Michowitz, A. Shimoni, and A. Nagler
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
Clin. Cancer Res., May 15, 2008; 14(10): 3044 - 3051.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Azuma, S. Yao, G. Zhu, A. S. Flies, S. J. Flies, and L. Chen
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Blood, April 1, 2008; 111(7): 3635 - 3643.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. A. Green, T. Okazaki, T. Honjo, W. J. Cook, and W. R. Green
The Programmed Death-1 and Interleukin-10 Pathways Play a Down-Modulatory Role in LP-BM5 Retrovirus-Induced Murine Immunodeficiency Syndrome
J. Virol., March 1, 2008; 82(5): 2456 - 2469.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zang and J. P. Allison
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Clin. Cancer Res., September 15, 2007; 13(18): 5271 - 5279.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. S. Webster, R. H. Thompson, K. J. Harris, X. Frigola, S. Kuntz, B. A. Inman, and H. Dong
Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine
J. Immunol., September 1, 2007; 179(5): 2860 - 2869.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
T. Okazaki and T. Honjo
PD-1 and PD-1 ligands: from discovery to clinical application
Int. Immunol., July 2, 2007; (2007) dxm057v1.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. Terawaki, Y. Tanaka, T. Nagakura, T. Hayashi, S. Shibayama, K. Muroi, T. Okazaki, B. Mikami, D. N. Garboczi, T. Honjo, et al.
Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function
Int. Immunol., July 2, 2007; (2007) dxm059v1.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Blood, July 1, 2007; 110(1): 296 - 304.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. R. Nazareth, L. Broderick, M. R. Simpson-Abelson, R. J. Kelleher Jr., S. J. Yokota, and R. B. Bankert
Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells
J. Immunol., May 1, 2007; 178(9): 5552 - 5562.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Nomi, M. Sho, T. Akahori, K. Hamada, A. Kubo, H. Kanehiro, S. Nakamura, K. Enomoto, H. Yagita, M. Azuma, et al.
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2151 - 2157.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Wolf, G. Li, A. Varadhachary, K. Petrak, M. Schneyer, D. Li, J. Ongkasuwan, X. Zhang, R. J. Taylor, S. E. Strome, et al.
Oral Lactoferrin Results in T Cell-Dependent Tumor Inhibition of Head and Neck Squamous Cell Carcinoma In vivo
Clin. Cancer Res., March 1, 2007; 13(5): 1601 - 1610.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, et al.
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
PNAS, February 27, 2007; 104(9): 3360 - 3365.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Y. Usui, Y. Okunuki, T. Hattori, M. Takeuchi, T. Kezuka, H. Goto, and M. Usui
Expression of Costimulatory Molecules on Human Retinoblastoma Cells Y-79: Functional Expression of CD40 and B7H1.
Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4607 - 4613.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
I. Kryczek, L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, et al.
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
J. Exp. Med., April 17, 2006; 203(4): 871 - 881.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. A. Laheru, D. M. Pardoll, and E. M. Jaffee
Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology
Mol. Cancer Ther., November 1, 2005; 4(11): 1645 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Tamura, K. Dan, K. Tamada, K. Nakamura, Y. Shioi, H. Hyodo, S.-D. Wang, H. Dong, L. Chen, and K. Ogata
Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia
Clin. Cancer Res., August 15, 2005; 11(16): 5708 - 5717.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Ohigashi, M. Sho, Y. Yamada, Y. Tsurui, K. Hamada, N. Ikeda, T. Mizuno, R. Yoriki, H. Kashizuka, K. Yane, et al.
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Clin. Cancer Res., April 15, 2005; 11(8): 2947 - 2953.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Saudemont, N. Jouy, D. Hetuin, and B. Quesnel
NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells
Blood, March 15, 2005; 105(6): 2428 - 2435.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Hirano, K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, et al.
Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
Cancer Res., February 1, 2005; 65(3): 1089 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
Y. Iwai, S. Terawaki, and T. Honjo
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Int. Immunol., February 1, 2005; 17(2): 133 - 144.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. H. Thompson, M. D. Gillett, J. C. Cheville, C. M. Lohse, H. Dong, W. S. Webster, K. G. Krejci, J. R. Lobo, S. Sengupta, L. Chen, et al.
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
PNAS, December 7, 2004; 101(49): 17174 - 17179.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y.-F. He, G.-M. Zhang, X.-H. Wang, H. Zhang, Y. Yuan, D. Li, and Z.-H. Feng
Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine
J. Immunol., October 15, 2004; 173(8): 4919 - 4928.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Saudemont and B. Quesnel
In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis
Blood, October 1, 2004; 104(7): 2124 - 2133.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
Clin. Cancer Res., August 1, 2004; 10(15): 5094 - 5100.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.